ALYREF and ovarian carcinoma: Further, ALYREF forms condensates in the nucleus of ovarian cancer cells, and depletion or mutation of ALYREF’s intrinsically disordered regions rescues its control on PARP10 mRNA nucleoplasmic distribution and stability, reduces tumor growth and is required for promotion of ovarian cancer aggressiveness and proliferation.